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ABSTRACT
The b-amyloid protein (Ab), the major component of the senile
plaques found in Alzheimer brains, derives from a larger b-amyloid
precursor protein (APP). Alternative splicing of the APP gene yields
three major APP messenger RNAs (mRNAs), which, in turn, give rise
to the APP770, APP751, and APP695 protein isoforms. In this study we
examined the effects of thyroid hormone on APP expression in N2a-b
neuroblastoma cells. T3 caused a significant increase in the APP770
mRNA band, in detriment of the APP695 mRNA, which was propor-
tionately reduced. In agreement with these results, T3 markedly al-
tered the relative ratio of intracellular APP isoforms, increasing the
amount of APP770 and causing an equivalent reduction of the imma-
ture APP695 isoform. In accordance with these results, the soluble
APP695-derived form was specifically reduced in the culture medium
obtained from T3-treated cells. In contrast, the increase in intracel-
lular APP770 was not followed by an enhanced release of soluble
derivatives of this isoform. These results suggest that T3 regulates not
only APP gene splicing, but also the processing and secretion of the
APP peptides. According to our results, thyroid hormone might play
a role in the development of Alzheimer’s disease by modulating the
intracellular and extracellular contents of APP isoforms. (Endocri-
nology 139: 2692–2698, 1998)
ALZHEIMER’S disease is a degenerative disorder of thecentral nervous system that causes mental deteriora-
tion and progressive dementia and is accompanied by neu-
ropathological lesions, including the presence of senile
plaques, of which the b-amyloid protein (Ab), a hydrophobic
39- to 43-residue amino acid peptide, is the major component
(1, 2). As illustrated in Fig. 1, the b-amyloid protein is pro-
teolytically derived from a set of alternatively spliced b-amy-
loid precursor proteins (APP) that are encoded by a single
gene located on human chromosome 21 (3). Expression of
APP plays a central role in Alzheimer’s disease, and it has
been suggested that an increase in the production of this
protein might actively contribute to the development of this
pathology (4–6). The APP gene is expressed in virtually all
mammalian tissues and gives rise to three major APP mes-
senger RNAs (mRNAs) that encode for the isoforms APP695,
APP751, and APP770, all of them containing the b-amyloid
peptide sequence. In addition, the 751 and 770 isoforms con-
tain a 56-amino acid Kunitz-type protease inhibitor domain.
The APP isoforms are membrane glycoproteins that are pro-
teolytically cleaved by the action of a set of enzymes referred
to generically as secretases (Fig. 1). The a-secretase cleaves
the protein between the residues Lys16 and Leu17 of the Ab
domain, precluding the generation of amyloidogenic frag-
ments (7, 8). Proteolytic cleavage of APP by a-secretase re-
sults in the release of soluble full-length amino-terminal frag-
ments (sAPP), which appear to be involved in neurotropic
events, such as neuronal development or neurite extension
(9). In contrast, the synthesis and release of amyloidogenic
fragments require the successive action of the b-secretase,
which cleaves the precursor at the amino-terminus of the Ab
sequence, and the g-secretase, which, in turn, cuts at posi-
tions 39–43 of this domain (10–12).
APP processing can be regulated by a variety of com-
pounds in a cell-dependent manner. Activation of the protein
kinase C or protein kinase A signal transduction pathways
specifically stimulates secretory nonamyloidogenic process-
ing, thus increasing the release of soluble fragments of APP
(13–16). A similar effect is induced by 17b-estradiol, a ligand
of the steroid/thyroid hormone superfamily of nuclear re-
ceptors, in a human breast carcinoma cell line (17). In con-
trast, overexpression of APP has been shown to induce the
activity of the alternative processing that generates the
b-amyloid peptide (18).
The antiprotease activity associated with Kunitz-contain-
ing APP peptides might locally affect its own processing.
Therefore, the relative ratio of Kunitz (770 and 751) to non-
Kunitz (695) isoforms may also play a role in Alzheimer’s
disease. In this respect, different factors, including retinoic
acid, another ligand of the nuclear receptor superfamily, can
specifically alter APP pre-mRNA splicing (19–22) and APP
processing (16, 23, 24) in a variety of cell types.
An apparent relationship between thyroid status and Alz-
heimer’s disease has been suggested. Hypothyroidism is ac-
companied by neurological symptoms that might, in a way,
resemble those observed in Alzheimer’s disease. Moreover,
and although a strong link between thyroid hormones and
Alzheimer’s disease has not been yet established, it has been
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suggested that a history of thyroid dysfunction might rep-
resents a risk factor for that pathology (25, 26). In addition,
thyroid hormones normally exert their action by binding to
nuclear receptors, and a reduction of thyroid hormone re-
ceptor mRNA levels in Alzheimer hippocampal cells has
been described (27).
In the present study, we examined the effects of T3 on the
splicing and secretion of APP in N2a-b neuroblastoma cells,
a stably transfected subline of N2a cells that expresses the b1
isoform of thyroid hormone receptor. Our results show that




DMEM and FCS were purchased from BioWhittaker (Verviers, Bel-
gium). Resin AG1X8 was obtained from Bio-Rad (Richmond, CA). Poly-
clonal antibody 369A against the cytoplasmic domain of APP (23) was
a gift from Dr. Samuel E. Gandy (Cornell University Medical Center,
New York, NY). The polyclonal antibody R7, recognizing the Kunitz
APP region (28), was a gift from Dr. N. Robakis (Mount Sinai School of
Medicine, New York, NY). The monoclonal antibody 22C11, which
recognizes the amino-terminus of APP, was purchased from Boehringer
Mannheim (Mannheim, Germany), and the 6E10 and 4G8 monoclonal
antibodies raised against the b-amyloid peptide were obtained from
Senetek (Maryland Heights, MO). The epitopes recognized by the dif-
ferent antibodies are depicted at the top of Fig. 1. The second biotinylated
antirabbit antibody and the peroxidase-conjugated streptavidin used in
Western blot analysis were purchased from Amersham International
(Aylesbury, UK). Reverse transcriptase and other reagents used for the
PCR analysis of DNA were obtained from Promega (Madison, WI).
Cell culture
Murine N2a-b neuroblastoma cells, a gift from Dr. Dussault (29), were
cultured in DMEM supplemented with 10% FCS depleted of thyroid
hormones by treatment with resin AG1X8, as previously described (30).
Previous to the experiments, cells were plated in 90-mm diameter cul-
ture tissue dishes (Falcon, Becton Dickinson, Plymouth, UK), and 24–48
h later were incubated in the absence or presence of T3. At the times
indicated in the text, media and cells were collected and stored frozen
until posterior analysis. Parental N2a cells were grown in medium
containing 10% FCS as described by Ortiz-Caro et al. (31), but the ex-
periments were carried out in the medium containing thyroid hormone-
depleted serum.
Western blot analysis
Cellular proteins were extracted by lysis with a buffer [150 mm NaCl,
50 mm Tris (pH 8), 2 mm EDTA, 1% Triton, and 0.1% SDS] containing
the protease inhibitors phenylmethylsulfonylfluoride (1 mm) and leu-
peptin (10 mg/ml). The protein content of cells was determined by using
the BCA assay (Pierce, Rockford, IL), according to the manufacturer’s
instructions. Equal amounts (40 mg) of cell extracts were then electro-
phoresed in an 8% SDS-polyacrylamide gel and transferred to an Im-
mobilon polyvinylidine difluoride membrane. Nonspecific binding was
blocked with 5% nonfat dried milk in Tris-buffered saline and 0.1%
Tween-20 for 2–3 h at room temperature, and cellular APP was detected
with a 1:1500 dilution of the rabbit polyclonal antibody 369A, raised
against the carboxyl-terminal domain of human APP, or with the same
dilution of the polyclonal antibody R7, which specifically recognizes the
Kunitz-containing isoforms of APP. After 1-h incubation at room tem-
perature, the membrane was washed and incubated with a second
biotinylated antirabbit antibody (1:2000) for an additional hour, washed
again, and finally incubated for 1 h with 1:2000 peroxidase-conjugated
streptavidin. All incubations took place at room temperature, and de-
tection by enhanced chemiluminiscence (ECL, Amersham International)
was carried out according to manufacturer’s indications. The monoclo-
nal antibody 6E10, which specifically recognizes the Ab-containing APP
isoforms, was used at a final concentration of 1.5 ml/ml.
Secreted full-length APP isoforms were detected by the same method
from 50 ml (1:100 from total) of conditioned medium using monoclonal
antibody 22C11 at a final concentration of 10 mg/ml. A minimal variation
of the method was introduced to detect the 4-kDa b-amyloid peptide in
the culture medium. In this case, 50- to 100-ml aliquots of medium were
electrophoresed in a 16.5% Tris-tricine gel, and the peptide was analyzed
with different dilutions (0.1–1.5 ml/ml) of anti-Ab monoclonal antibod-
ies 6E10 and 4G8.
The apparent molecular mass (kilodaltons) of the detected bands was
always determined using a wide range protein standard (Mark 12 from
NOVEX, San Diego. CA). The intensity of the bands was quantified by
densitometric scan of the autoradiograms, and the results for a particular
isoform are expressed as a percentage of the total APP, either cellular or
soluble.
RT-PCR amplification of mRNA
RT-PCR was used to analyze the differential expression of APP
mRNA isoforms. Two oligonucleotides that flanked exons 6 and 9 of the
APP gene were used. The forward primer was 59-TGAAGACAAAG-
TAGTAGAAGT-39, and the reverse primer was 59-ACCTGGGACAT-
TCTCTCTCGGTGCTTGGC-39. Total RNA was extracted from cell cul-
tures by the guanidine thiocyanate method (32), and first strand
complementary DNA (cDNA) synthesis was performed on 5–6 mg RNA
using 20 U AMV reverse transcriptase and 100 ng reverse primer. The
PCR reaction was set up using the cDNA previously obtained in a
FIG. 1. Schematic diagram of the APP,
showing its location in the membrane
and the position of the alternatively
spliced exons 7 (Kunitz domain) and 8
(Spl.8). The APP770 isoform contains
both sequences, whereas APP751 only
contains the Kunitz region. Both do-
mains are absent in the APP695 isoform.
The diagram also shows the epitopes of
the various antibodies used. Cleavage
sites for a, b, and g secretases have been
identified with arrows.
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standard 100-ml buffer containing 5 U Taq polymerase and 100 ng of the
appropriate primers. These primers were chosen to generate fragments
of 562, 505, and 337 bp corresponding to the three major mRNA isoforms.
Samples were subjected to 25–30 cycles of amplification (denaturation
at 94 C for 1 min, annealing at 55 C for 1 min, and extension at 72 C for
2 min). PCR products were analyzed on 3% NuSieve-GTG agarose and
visualized by ethidium bromide staining.
Statistics
Unless indicated otherwise, all data points are the mean of at least
duplicate cultures that did not normally vary by more than 10–15% or
are the mean 6 sem of the results obtained in at least three separate
experiments performed in duplicate. The significance of differences was
calculated with Student’s test.
Results
Effects of T3 on the cell-associated APP protein
Cellular APP isoforms were detected from cell lysates by
Western blot using antibody 369A. As illustrated in Fig. 2A,
5 nm T3 induced a significant change in the pattern of in-
tracellular APP species, mainly affecting the 95- and 125-kDa
bands. Based upon earlier reports (23, 24, 33), the smallest
95-kDa band could represent the immature APP695 isoform,
whereas the lowest mobility bands more likely represent the
mature Kunitz-containing APP770 and APP751 species. Ac-
cording to this, T3 consistently induces a reduction of im-
mature APP695 as well as an increase in the mature APP770
form after 24–48 h of treatment. In addition, the intermediate
bands do not appear to be affected by the thyroid hormone.
However, a complete definition of those intermediate bands
has not been possible, and a specific modification of one of
those species cannot be definitely discarded. Figure 2B il-
lustrates the densitometric quantitation of the different
bands at 48 h of treatment. The intensity of the 95-kDa band,
which represents the immature APP695 isoform, was reduced
to less than 50% of the control value, whereas the 125-kDa
band (APP770) was increased by more than 2-fold in the cells
after T3 treatment. As indicated above, the bands from 105–
118 kDa, which were considered a unique species in the
densitometric analysis, were not affected by T3. No effects
were detected either in N2a-b cells before 12 h of T3 treatment
or in parental N2a cells, in which the nuclear T3 receptor is
expressed at very low concentrations, at any of the time
periods analyzed (data not shown).
The effect of T3 on the APP770 isoform was confirmed in
two separate experiments performed with the R-7 antibody,
which specifically recognizes the Kunitz-containing APP iso-
forms (28). Identical results were obtained in both experi-
ments. As illustrated in Fig. 3, thyroid hormone induces a
specific increase in the slowest mobility band, which corre-
sponds to the APP770 isoform. The effect was observed after
24–48 h of treatment with 0.1 or 5 nm T3, although the
increase was less marked with the lowest hormone concen-
tration. As expected, the results were essentially identical to
those observed using the 369A antibody, and the Kunitz-
containing APP770 was increased by approximately 2-fold in
N2a-b cells incubated in the presence of 5 nm T3 for 48 h.
Antibody 369A can also recognize different isoforms of
APLP, an amyloid precursor-like protein that is identical to
APP except for the lack of the Ab sequence. One of these
isoforms, which contains 695 residues (APLP695), might run
together with APP695. Cultured neuronal cells normally ex-
press very low levels of APLP695 (34), and it is unlikely that
this isoform could interfere and mask the effect of T3 on APP
in N2a-b cells. However, to definitely establish the identity
and regulation of APP695, we performed additional experi-
ments using monoclonal antibody 6E10, which specifically
recognizes APP, but not APLP, isoforms. As shown in Fig.
4A, antibody 6E10 detects a band identical to the 95-kDa
species observed with the 369A antibody. As illustrated in
Fig. 4B, the regulation of this band is also identical to that
obtained with antibody 369A. These results confirm those
presented in Fig. 2, and although we cannot discard a pos-
sible contribution of APLP forms to the species detected with
FIG. 2. Western blot analysis of cell-associated isoforms of APP. Cel-
lular proteins were extracted by lysis from cells previously incubated
in the absence or presence of 5 nM T3. At the indicated times, samples
containing 40 mg protein were electrophoresed in an 8% polyacryl-
amide gel and transferred to an Immobilon membrane. The immu-
noreactive bands were analyzed with carboxyl-terminal antibody
369A and visualized by ECL. A, Autoradiogram of a representative
experiment. The apparent sizes (kilodaltons) of bands are indicated
at the left. B, Densitometric analysis of bands obtained from cells
incubated with T3 for 48 h. The intermediate bands containing the
105- to 118-kDa isoforms have been considered as a single species.
Data are the average 6 SE from three separate experiments performed
in duplicate and are expressed as a percentage of the total content of
immunoreactive bands. Controls are untreated N2a-b cells. In this
and subsequent figures: *, P , 0.05; **, P , 0.01.
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the antibody 369A, it can be concluded that T3 specifically
decreases the cellular content of APP695.
Influence of T3 on the accumulation of APP secreted forms
into the culture medium
The full-length soluble derivatives of APP released into the
culture medium were analyzed with monoclonal antibody
22C11. A similar pattern of bands was observed at the two
time points studied, 24 and 48 h. As shown in Fig. 5, incu-
bation of cells with 5 nm T3 resulted in a significant and
specific reduction of the 93-kDa band, which represents the
sAPP695 species accumulated in the medium. As observed in
Fig. 5B, the intensity of the 93-kDa band was reduced to
approximately 50% of the control value after 48 h of incu-
bation with T3. As occurred with the cell-associated APPs,
these effects were not observed in the parental N2a cell line.
However, and contrary to the effect observed on the intra-
cellular pattern of proteins, no significant differences in the
intensity of the soluble Kunitz-containing bands were ob-
served at 24 or 48 h between the T3 and control groups. Taken
together, these results suggest that thyroid hormones may
selectively affect not only the processing but also the release
of APP.
Effects of T3 on APP mRNA isoforms
To examine whether the specific changes induced by T3 on
the cellular APP isoforms were the result of changes in the
alternative splicing of the APP mRNA precursor, we ana-
lyzed the relative ratios of the different mRNA isoforms by
RT-PCR. The alternative splicing pattern of exons 7 and 8 was
studied using primers that amplify sequences between exons
6 and 9. Three major bands were detected at the expected
positions of 562 bp (APP770), 505 bp (APP751), and 337 bp
(APP695). Figure 6 illustrates the results obtained in a rep-
resentative experiment in which the cDNA was amplified
through 30 cycles. Similar results were obtained in an addi-
FIG. 3. Western blot analysis of Kunitz-containing isoforms in N2a-b
cells. Proteins obtained from N2a-b cells incubated in the absence
(control) or presence of 0.1 or 5 nM T3 for 24–48 h were analyzed with
R7 antibody. A, A characteristic autoradiogram; B, densitometric
quantitation of the slowest mobility band (APP770) in the group of cells
incubated for 48 h. Each bar in B is representative of four datasets
(two separate experiments performed in duplicate) in control and 5 nM
T3-treated cells and is representative of only two datasets (duplicates
of one experiment) in the 0.1 nM T3-treated cells. The cellular content
of APP770 has been expressed as a percentage of the total APP de-
tected.
FIG. 4. Specific detection of APP isoforms with monoclonal antibody
6E10. Cellular proteins were extracted by lysis from N2a-b cells
incubated in the absence (control) or presence of 5 nM T3 for 24–48
h, and aliquots of 40 mg protein were analyzed by Western blot with
monoclonal antibody 6E10. Results were essentially identical in two
separate experiments. A, Autoradiogram of a representative exper-
iment. The apparent size (kilodaltons) of the highest mobility band is
indicated at the right by an arrow. B, Densitometric analysis of the
95-kDa band obtained from cells after 48 h of incubation.
THYROID HORMONES REGULATE SPLICING AND SECRETION OF APP 2695
 by on May 10, 2010 endo.endojournals.orgDownloaded from 
tional experiment performed under the same conditions and
in two separate experiments performed with only 25 cycles.
Although under our conditions the RT-PCR analysis is not
quantitative, the relative abundance of bands was essentially
identical after 25 or 30 cycles, thus indicating that in that
phase the intensity of bands is proportional to the initial
concentration of the corresponding isoforms.
As shown in Fig. 6, incubation of cells for 48 h with 5 nm
T3 significantly altered the splicing pattern, decreasing the
content of APP695 in favor of the APP770 form. Thus, T3
treatment led to a pattern of isoforms that, to some extent,
resembled that in nonneuronal cells. The effect was not yet
evident at 24 h of incubation (data not shown), but it was
maintained after 72 h of treatment.
Discussion
Expression and metabolism of APP play a central role in
the development of Alzheimer’s disease. It has been previ-
ously described that ligands of nuclear receptors, such as
17b-estradiol or retinoic acid, the active metabolite of vitamin
A, are involved in the splicing and/or processing of APP (17,
20–22). In this study, we have demonstrated that T3, another
ligand of the nuclear receptor superfamily, could also play an
important role in the regulation of these processes.
T3, the more active form of the thyroid hormones, specif-
ically alters APP gene splicing in N2a-b neuroblastoma cells,
decreasing the relative amount of APP695 mRNA in favor of
APP770 mRNA, which encodes a Kunitz-containing form.
The changes induced by T3 give rise to a pattern of APP
mRNA that, to some extent, resembles that of peripheral and
nonneuronal cells.
The precise mechanism(s) involved in the regulation of
APP by this hormone remains unclear. However, the lack of
effect of T3 on APP expression in the parental N2a cell line,
which expresses very low levels of hormone receptor (31),
strongly suggests a receptor-mediated mechanism. The ef-
fects induced by the thyroid hormone on the pattern of APP
mRNA isoforms could be secondary to the regulation of
specific factors involved in the alternative splicing of the
gene. In this respect, thyroid hormone as well as retinoic acid
can regulate the expression of SmN, a specific splicing pro-
tein that is only expressed in adult heart and brain (35).
Although the precise function of this protein remains un-
clear, this finding suggests a potential role of this or another
yet unidentified splicing factor in the response of neuronal
cells to thyroid hormones.
T3 alters the intracellular pattern of the APP isoforms,
leading to a significant reduction of the immature non-
Kunitz APP695 isoform and an increase in the Kunitz-con-
taining mature forms. This pattern of intracellular proteins
shows a good correlation with the T3-induced distribution of
APP mRNA isoforms and is probably the direct result of the
alternative mRNA splicing. In contrast, the parallelism be-
tween the mRNA and cellular holoprotein patterns could not
be extended to the T3-induced changes in the sAPP isoforms
released to the culture medium. Treatment of N2a-b cells
with T3 leads to a diminished accumulation of sAPP695, but
not to an increase in other soluble isoforms.
Additionally, efforts have been made to detect the amyloid
peptide in the medium. Unfortunately, the levels of Ab pro-
duced from endogenous APP in N2a-b cells are extremely
low, and this precludes a reliable observation of the peptide.
As the pattern of released forms in the T3-treated cells did
FIG. 6. Amplification and analysis of RNA by RT-PCR. The presence
of the transcripts that encode the different APP isoforms was ana-
lyzed by RT-PCR in cells incubated in the absence (0 h) or presence
of 5 nM T3 for 48 and 72 h. The figure illustrates duplicates of a
representative experiment. Three bands of 562, 505, and 337 bp,
which correspond to the major mRNA isoforms (770, 751, and 695),
were observed.
FIG. 5. Regulation of APP secretion by T3. After 24 or 48 h of incu-
bation of N2a-b cells in the absence or presence of 5 nM T3, the secreted
APP isoforms were analyzed by Western blot with monoclonal anti-
body 22C11 in 50-ml aliquots (1% of total) of conditioned medium. A,
Autoradiogram for a representative experiment. The exposure time
was longer for the 24-h culture groups. B, Densitometric quantifica-
tion of the Kunitz-containing band and the 93-kDa band (APP695
derivative) in the culture medium after 48 h of incubation. Data are
the average 6 SE from three separate experiments performed in du-
plicate and are expressed as a percentage of the total APP secreted
forms.
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not correlate with the pattern of cellular APP, it might be
speculated that T3 can regulate the synthesis and/or activity
of some protease(s) involved in the metabolism of this pre-
cursor. In this respect, it has been reported that tacrine, a
drug extensively used for the treatment of Alzheimer’s dis-
ease, effectively reduces the secretion of soluble APP deriv-
atives by a mechanism that probably involves inhibition of
an acetylcholinesterase-associated proteolytic activity (36).
As the effects of tacrine in human neuroblastoma IMR-32
cells in part resemble those elicited by T3 in N2a-b cells, a
similar mechanism might be proposed. However, the dif-
ferential effect exerted by T3 on the secretion of soluble
APP695 and APP770/751 into the culture medium suggests a
more complex mechanism involving additional effects of the
thyroid hormones in the regulation of sAPP secretion. Fur-
ther experiments will be necessary to clarify the mechanisms
by which thyroid hormones regulate the processing and re-
lease of APP isoforms.
The relevance of our results for the management of Alz-
heimer’s patients is still unclear at present. On the one hand,
it has been reported that isoforms containing the Kunitz
protease inhibitor domain are preferentially expressed in the
Alzheimer brain (37), whereas the 695 form is reduced (4).
According to these descriptions, the thyroid hormones
should be considered a risk factor because they induce a
pattern of APP in which the Kunitz-containing forms are
preferentially expressed. On the other hand, it has been sug-
gested that deposition of b-amyloid in senile plaques may be
mainly derived from APP695. In agreement with these re-
ports, thyroid hormones might protect against the amyloid
deposition by decreasing the presence of APP695 and its
soluble derivative sAPP isoform into the cells and the ex-
tracellular space, respectively.
It is evident that new experiments should be performed to
fully understand the role of thyroid hormone in Alzheimer’s
disease. However, the results described in the present work
support the idea that thyroid hormones might play a role in
this pathology by modulating the cellular and extracellular
content of APP transcripts through a mechanism that prob-
ably involves binding to the nuclear receptor and expression
of genes that encode different splicing factors that must be
identified in future studies. In addition, and as T3 receptor
mRNA levels are decreased in Alzheimer hippocampal cells
(27), the cellular sensitivity to T3 might be affected in Alz-
heimer’s disease.
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